Back to top
more

Illumina (ILMN)

(Delayed Data from NSDQ)

$97.76 USD

97.76
2,487,411

-0.68 (-0.69%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $97.76 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Sweta Killa headshot

Trade War Heats Up: ETFs to Shield Your Portfolio

by Sweta Killa

The tit-for-tat tariffs ignite fears of a trade war, prompting investors to dump riskier assets and take a flight to safety.

Zacks Equity Research

Analysts Estimate Sage Therapeutics, Inc. (SAGE) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Sage Therapeutics (SAGE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Should SPDR S&P MidCap 400 ETF (MDY) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for MDY

Zacks Equity Research

Curious about Illumina (ILMN) Q4 Performance? Explore Wall Street Estimates for Key Metrics

by Zacks Equity Research

Besides Wall Street's top -and-bottom-line estimates for Illumina (ILMN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2024.

Zacks Equity Research

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

by Zacks Equity Research

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Zacks Equity Research

Illumina (ILMN) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Illumina (ILMN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Here's Why Illumina (ILMN) is a Strong Momentum Stock

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

by Zacks Equity Research

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Zacks Equity Research

Why Illumina (ILMN) is Poised to Beat Earnings Estimates Again

by Zacks Equity Research

Illumina (ILMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Equity Research

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

by Zacks Equity Research

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Zacks Equity Research

Illumina Partners NVIDIA for Genomic Advancements, ILMN Stock Climbs

by Zacks Equity Research

ILMN teams up with NVIDIA to advance technology platforms for the analysis and interpretation of multiomic data.

Zacks Equity Research

Should SPDR Portfolio S&P 400 Mid Cap ETF (SPMD) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for SPMD

Zacks Equity Research

Should Vanguard S&P Mid-Cap 400 Value ETF (IVOV) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for IVOV

Zacks Equity Research

ILMN Stock Set to Gain From Latest Updates to the NovaSeq X Series

by Zacks Equity Research

Illumina advances NovaSeq X Series with a software upgrade and the new 25B 100-cycle and 200-cycle kits.

Zacks Equity Research

Should iShares Core S&P Mid-Cap ETF (IJH) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for IJH

Zacks Equity Research

Should iShares S&P Mid-Cap 400 Value ETF (IJJ) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for IJJ

Debanjana Dey headshot

Tempus AI Stock Plunges 28.9% in Three Months: What's Next?

by Debanjana Dey

TEM is enhancing its offerings and expanding the breadth of products and services to improve patient care. However, macro challenges are likely to hurt its performance.

Zacks Equity Research

Should Vanguard S&P Mid-Cap 400 ETF (IVOO) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for IVOO

Urmimala Biswas headshot

TMO Institutional & Insider Stock Sell-Offs Upset Market: How to Play

by Urmimala Biswas

Investors are also concerned about Thermo Fisher's continuous decline in testing revenues due to the decline in COVID testing-related demand.

Zacks Equity Research

Should SPDR S&P MidCap 400 ETF (MDY) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for MDY

Zacks Equity Research

Illumina (ILMN) Down 9.3% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Illumina (ILMN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Should SPDR S&P 400 Mid Cap Value ETF (MDYV) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for MDYV

Zacks Equity Research

MYGN Stock Up on Integration of HRD Platform Into Illumina's TSO 500 v2

by Zacks Equity Research

Myriad Genetics incorporates its proprietary HRD platform in Illumina's updated TruSight Oncology 500 v2 comprehensive gene panel assay.

Zacks Equity Research

ILMN Stock Set to Gain From Expansion of TruSight Oncology Portfolio

by Zacks Equity Research

Illumina's new TSO 500 v2 assay aims to enable CGP of tumors, bolstering its TruSight Oncology portfolio.

Zacks Equity Research

Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?

by Zacks Equity Research

Sector ETF report for PBE